Ruxolitinib Response in Teens, Adults With Vitiligo Compared

Pooled data from the phase 3 TRuE-V1 and TRuE-V2 studies were used to evaluate responses in a subset of adolescents treated with the topical JAK inhibitor for vitiligo.

Related Keywords

France ,India ,Mumbai ,Maharashtra ,Singapore ,Shital Poojary ,Drug Administration ,University Of Bordeaux ,European Medicines Agency ,Research Center ,World Congress ,Vitiligo Area Scoring Index ,Julien Seneschal ,Steady Improvement ,Medscape Medical News ,Presented July ,Adolescent Medicine ,Vitiligo ,Leukoderma ,Acne ,Acne Vulgaris ,Practice Management ,Patient Safety ,Adverse Effects ,Side Effects ,Autoimmune Disease ,Contusion ,Clinical Research ,Clinical Trials ,Linical Studies ,Europe ,European ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Hospitals ,Kidneys ,Pathogenesis ,Pruritus ,Pruritis ,Pitch ,